Feasibility of VECOPA, a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trial

References

• Schellong G, Brämswig J, Ludwig R, et al. Combined treatment strategy in over 200 children with Hodgkin's disease: graduated chemotherapy, involved field irradiation with low dosage and selective splenectomy. A report of the cooperative therapy study DAL-HD-82. Klin Pädiatr 1986;198:137–146.
   PubMed Web of Science ®Google Scholar
• Behringer K, Mueller H, Goergen H, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 2013;31:231–239.
   PubMed Web of Science ®Google Scholar
• Brämswig JH, Heimes U, Heiermann E, et al. The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin's disease during childhood or adolescence. Cancer 1990;65:1298–1302.
   PubMed Web of Science ®Google Scholar
• Harel S, Fermé C, Poirot C. Management of fertility in patients treated for Hodgkin's lymphoma. Haematologica 2011;96: 1692–1699.
   PubMed Web of Science ®Google Scholar
• Hassel JU, Brämswig JH, Schlegel W, et al. Testicular function after OPA/COMP chemotherapy without procarbazine in boys with Hodgkin's disease. Results in 25 patients of the DAL-HD-85 study. Klin Pädiatr 1991;203:268–272.
   PubMed Web of Science ®Google Scholar
• Kiserud CE, Fosså A, Bjøro T, et al. Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer 2009;100:455–463.
   PubMed Web of Science ®Google Scholar
• Schellong G, Hörnig I, Brämswig J, et al. Zur Bedeutung des Procarbazins in der Chemotherapie des Morbus Hodgkin – Ein Bericht der kooperativen Therapiestudie DAL-HD-85. Klin Pädiatr 1988;200:205–213.
   PubMed Web of Science ®Google Scholar
• Schellong G, Pötter R, Brämswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999;17: 3736–3744.
   PubMed Web of Science ®Google Scholar
• Mauz-Körholz C, Hasenclever D, Dörffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 2010;28: 3680–3686.
   PubMed Web of Science ®Google Scholar
• Whitlock JA, Greer JP, Lukens JN. Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia. Cancer 1991;68:600–604.
   PubMed Web of Science ®Google Scholar
• Winick NJ, McKenna RW, Shuster JJ, et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukaemia treated with etoposide. J Clin Oncol 1993;11:209–217.
   PubMed Web of Science ®Google Scholar
• Gerres L, Brämswig JH, Schlegel W, et al. The effects of etoposide on testicular function in boys treated for Hodgkin's disease. Cancer 1998;83:2217–2222.
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Beyer J, Droz JP, et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998;16:3386–3391.
   PubMed Web of Science ®Google Scholar
• Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012;379:1791–1799.
   PubMed Web of Science ®Google Scholar
• Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 2010;55:1145–1152.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745–751.
   PubMed Web of Science ®Google Scholar
• Meadows AT, Obringer AC, Marrero O, et al. Second malignant neoplasms following childhood Hodgkin's disease: treatment and splenectomy as risk factors. Med Pediatr Oncol 1989;17:477–484.
   PubMedGoogle Scholar
• Riepenhausen M, Schellong G, Gadner H, et al. Risk of secondary leukemias after combined modality treatment without mechlorethamine in childhood Hodgkin's disease (HD) - experience in 667 patients treated in 4 German-Austrian trials. Med Pediatr Oncol 1994;23:175A [Abstract].
   Google Scholar
• Schellong G, Riepenhausen M, Creutzig U, et al. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group. J Clin Oncol 1997;15:2247–2753.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Brosteanu O, Gerike T, et al. Modelling of chemotherapy: the effective dose approach. Ann Hematol 2001;80(Suppl. 3):B89–B94.
   PubMed Web of Science ®Google Scholar
• Rühl U, Albrecht M, Dieckmann K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 2001;51:1209–1218.
   PubMed Web of Science ®Google Scholar
• Kurch L, Mauz-Körholz C, Bertling S, et al. The EuroNet Pediatric Hodgkin Network - modern imaging data management for real time central review in multicentre trials. Klin Pädiatr 2013;225:357–361.
   PubMed Web of Science ®Google Scholar
• Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: Version 2.0--An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:13–47.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar